Virtus LifeSci Biotech Products ETF (BBP)
| Assets | $17.11M |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Shares Out | 350,000 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +13.27% |
| Volume | 352 |
| Open | 49.50 |
| Previous Close | 48.89 |
| Day's Range | 49.37 - 49.50 |
| 52-Week Low | 34.12 |
| 52-Week High | 53.06 |
| Beta | 0.74 |
| Holdings | 60 |
| Inception Date | Dec 17, 2014 |
About BBP
The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is managed by Virtus Investment Partners.
Top 10 Holdings
27.80% of assets| Name | Symbol | Weight |
|---|---|---|
| Provention Bio, Inc. | PRVB | 4.41% |
| Aurinia Pharmaceuticals Inc. | AUPH | 4.28% |
| BridgeBio Pharma, Inc. | BBIO | 3.26% |
| Seagen Inc. | SGEN | 2.72% |
| Mirum Pharmaceuticals, Inc. | MIRM | 2.30% |
| Apellis Pharmaceuticals, Inc. | APLS | 2.23% |
| Travere Therapeutics, Inc. | TVTX | 2.20% |
| PTC Therapeutics, Inc. | PTCT | 2.16% |
| ACADIA Pharmaceuticals Inc. | ACAD | 2.13% |
| Exelixis, Inc. | EXEL | 2.10% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 20, 2017 | $0.0723 | Dec 27, 2017 |
| Dec 21, 2015 | $0.39725 | Dec 29, 2015 |
News
5 Least-Hurt Biotech ETFs of the Last Week
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
2 Sector ETFs Hovering Around a 52-Week High
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
Biotech Wins Last Week: 5 Best ETFs
The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal
Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Vir...
Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics
Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday...
5 ETFs Riding High on the Biotech Comeback
Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.
Biotech ETFs Are Making a Comeback
Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech ...
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
Beyond Clean Energy, 5 Sector ETFs Soaring to Record Highs
As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading s...
4 ETFs to Play the Hot Events of Q4
The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.
Top-Performing ETFs of the Worst September Since 2011
After a superb August, September turned gloomy for Wall Street.
5 ETFs Shining Bright Amid September Selling
The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.
"Worst September in 18 Years"? 4 Sector ETFs Surviving Selloffs
After a superb August, September looks gloomy for Wall Street. Still,
Late-stage biotech ETFs rally Monday on virus treatment hopes
Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF ...
Biotech ETFs Surge on a Flurry of Positive News
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
ACADIA Pharmaceuticals Help Lift Biotech ETFs
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS:...
Biotechnology Market on a Tear: 5 ETFs in Spotlight
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
A Spread of Top-Ranked ETFs That Crushed the Market in Q1
We are presenting a bunch of top performing ETFs of the first quarter with a solid Zacks ETF Rank #1 or 2 which are expected to outperform in the quarter ahead.